

PRESS RELEASE

Stockholm, 30 September 2015



New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

The total number of shares in Swedish Orphan Biovitrum AB (publ) as per 30 September 2015 amounts to 271,822,806 shares, whereof 270,389,770 common shares and 1,433,036 class C shares, corresponding to in total 270,533,073.6 votes. The increase in the number of shares and votes results from an issue of 1,036,856 class C shares under Swedish Orphan Biovitrum's incentive program. The class C shares are intended to ensure fulfillment of commitments under incentive programs. The company holds 2,763,768 common shares and all 1,433,036 class C shares.

About Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.

For more information please contact

Media relations

Oskar Bosson, Head of Communications

T: +46 70 410 71 80

oskar.bosson@sobi.com

Investor relations

Jörgen Winroth, Vice President, Head of Investor Relations

T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135

jorgen.winroth@sobi.com

The above information has been made public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 30 September 2015 at 08:00 CET.